Infectious disease
The U.S. – and global – response to the COVID-19 pandemic has been volatile at best. This is fair, considering that SARS-CoV-2 is a novel virus with a lethality we haven’t seen in more than a century.
The decision to halt critically ill patients was made in response to Regeneron’s independent safety board finding a potential safety signal and an unfavorable risk-benefit profile of the monoclonal antibody therapy in a subgroup of patients requiring high-flow oxygen or mechanical ventilation.
A seroprevalance study of 15,591 children in Bavaria, published October 28th in Med, revealed a six-fold greater prevalence of the SARS-CoV-2 virus than reported cases.
Novo Nordisk announced today that it has ended its development of the anti-IL-21 antibody NN9828 in combination with Victoza. The decision was made after analyzing Phase II clinical trial data in patients with Type 1 diabetes.
It was a particularly busy week for announcements about clinical trials, both related to COVID-19 and everything else. Here’s a look.
The positive findings were shared as part of the company’s Emergency Use Authorization submission for its investigational COVID-19 therapy.
Fauci said the first COVID-19 vaccines could ship late December or early January.
BioSpace provides an up-to-date overview of these deals and the projected COVID-19 vaccine doses each company plans to have within the next couple of years.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
Recent Greenphire data shows new participant enrollment up 85% since slump in April.
PRESS RELEASES